Navigation Links
NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
Date:4/30/2008

NightHawk Radiology (Nasdaq: NHWK), headquartered in Coeur d'Alene, Idaho, is leading the transformation of the practice of radiology by providing high-quality, cost-effective solutions to radiology groups and hospitals throughout the United States. NightHawk provides the most complete suite of solutions, including professional services, business services, and its advanced, proprietary clinical workflow technology, all designed to increase efficiencies and improve the quality of patient care and the lives of physicians who provide it. NightHawk's team of U.S. board-certified, state-licensed, and hospital-privileged physicians located in the United States, Australia, and Switzerland, provides services 24 hours a day, seven days a week, for more than 750 radiology group customers and the 26% of all U.S. hospitals they serve. For more information, visit http://www.nighthawkrad.net.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding the company's growth strategy and the contribution of David Engert to the Company in his role as a member of the Board of Directors. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with general economic conditions, competitive conditions in the radiology industry, and regulatory risks. Other factors that could cause operating and financial results to differ are described in the company's prospectus and periodic reports filed with the Securities and Exchange
'/>"/>

SOURCE NightHawk Radiology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
2. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
3. NightHawk Radiology Holdings, Inc. to Speak at Annual Piper Jaffray Healthcare Conference on November 28, 2007
4. NightHawk Radiology: One Source, One Solution
5. NightHawk Radiology Holdings, Inc. to Speak at Annual JPMorgan Healthcare Conference on January 10, 2008
6. NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results
7. NightHawk Radiology Holdings, Inc. Announces Date for Fourth Quarter and Full-Year 2007 Earnings Conference Call
8. NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative
9. NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call
10. NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance
11. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...n May Be Revealed Friday, January 9 , , WASHIN...rvice Employees International Union (SEIU) Preside...IU International Executive Board to discuss the fo...members out of SEIU United Healthcare Workers-West...he final decision until tomorrow. , , According...
(Date:1/8/2009)... Jude study could shape new treatments for seconda...wire-USNewswire/ -- Scientists at St. Jude Childre...ective treatment for bacterial pneumonia following...mycin and azithromycin, which kill bacteria by inh...e than a standard first-line treatment with the "b...
(Date:1/8/2009).... Jude Children,s Research Hospital have demonstra...onia following influenza. They found that the anti...acteria by inhibiting their protein synthesis, are...nt with the "beta-lactam" antibiotic ampicillin, w...The finding is important because pneumonia, rather...
(Date:1/8/2009)...d Acquisition in 2009 Continues Growth Trend , ,...tCall/ -- IPC The Hospitalist Company, Inc. (Nasda...ian group practice company, announced today that i... Acute Care Consultants, Inc. (MACC) in St. Louis,...pansion in the St. Louis market, where IPC has est...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2
...bosis is a serious complication that can occur in ...and can in turn lead to heart attack, pulmonary em... the result of a research performed in Italy by th...l Epidemiology and the Onco-Haematology Unit of th...
...ics researchers at the Children's Hospital of Phil... Alagille syndrome, a developmental disease with a...inding may have broader implications in the unders...e Children's Hospital team had earlier discovered ...
...g solid food to infants less than six months old i... allergies later and new moms should rather breast...ds of all types should be avoided for the first si... milk, eggs, fish, and nuts should not be introduc...
...dy carried out on approximately 9,000 Danish resid...2 gene might increase three-fold// a woman's risk ...tudy, which was the first to examine the prevalenc...iated with it, in the general population, will be ...
Other Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:Second Alagille Syndrome Gene discovered: More information on kidney disease 2Health News:CHEK 2 Gene Mutation Triples Breast Cancer Risk 2
(Date:1/8/2009)..., Mass. and COLUMBUS, Ohio, Jan. 8 ...prietary nucleic acid assays, today announced that...al Quantitative Assay are complete. , , Under ...linearity, specificity and reproducibility and rob...termined. The data obtain agreed with internally g...
(Date:1/7/2009)...Tenn., Jan. 7 Scientist... a high likelihood of relapse in children with acu...archers caution that further research is needed to... or IKAROS, lead to leukemia relapse, the findin...nostic tests to assess the risk of treatment failu...
(Date:1/7/2009)...Several Products in Development Based On Osteotech...ate Natural BioRegeneration; FDA Filing Anticipate...an. 7 Osteotech, Inc. ...of biologic products for regenerative healing, ann...cal trial for its DuraTech(TM) BioRegeneration Mat...
(Date:1/6/2009)...xpands on Successful Results from prior U.S., U.K....wire/ -- Vital Therapies, Inc. (VTI), a developmen...ounced patient enrollment has begun for a randomiz...al that will study the Extracorporeal Liver Assist...ute Liver Failure (ALF) under three protocols. The...
Breaking Medicine Technology:Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 2Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 7233 1University of Pennsylvania study reveals inconspicuous hosts in the Lyme disease epidemic 7233 2SEIU Endorses Anderson Perea and Perea in Fresno 7229 1SEIU Endorses Anderson Perea and Perea in Fresno 7229 2FDA Sunscreen Labeling Decision Delayed Another Month Leading U S Physician to Say Enough Is Enough 7225 1FDA Sunscreen Labeling Decision Delayed Another Month Leading U S Physician to Say Enough Is Enough 7225 2Neptune Technologies 26 Bioressources Inc Secures Access to Nationwide Consumer Mass Market in the United States 2013 1Neptune Technologies 26 Bioressources Inc Secures Access to Nationwide Consumer Mass Market in the United States 2013 2Neptune Technologies 26 Bioressources Inc Secures Access to Nationwide Consumer Mass Market in the United States 2013 3
...--(BUSINESS WIRE)--Jun 12, 2007 - Critical,Therape...lication,of data from a pivotal Phase III clinical... tablets in the June 2007 issue of the,Journal of ... Drug,Administration (FDA) on May 30, 2007. Critic...rtner Dey, L.P. (DEY), expects to,begin marketing ...
...ted at EULAR Confirms Efficacy with Either Every,T... June 2007 - 7:00 am CET - New pivotal data,(RAPID...ongress of,Rheumatology (EULAR) show that Cimzia (...anti-TNF, combined with methotrexate,therapy has a...s,and symptoms of active rheumatoid arthritis (RA)...
Other Medicine Technology:Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications.
DyNA Quant™ 200 is a fixed wavelength fluorometer for 365 nm excitation and 460 nm emission. The spectral characteristics are specifically designed for the detection of double-stranded DNA using
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates.
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C
Medicine Products: